Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 440Rectal Neoplasms 209Colonic Neoplasms 201Pancreatic Neoplasms 131Stomach Neoplasms 116Neoplasm Metastasis 97Neoplasms 63Esophageal Neoplasms 56Precursor Cell Lymphoblastic Leukemia-Lymphoma 51Lymphoma 49Leukemia 41Carcinoma, Hepatocellular 40Adenocarcinoma Of Esophagus 37Burkitt Lymphoma 33Adenocarcinoma 29Cholangiocarcinoma 26Biliary Tract Neoplasms 22Carcinoma, Non-Small-Cell Lung 21Gastrointestinal Neoplasms 20Lymphoma, Non-Hodgkin 19Gallbladder Neoplasms 19Esophageal Squamous Cell Carcinoma 15Osteosarcoma 14Bile Duct Neoplasms 14Unspecified Adult Solid Tumor, Protocol Specific 13Lymphoma, Large B-Cell, Diffuse 13Liver Neoplasms 13Leukemia, Biphenotypic, Acute 13Ovarian Neoplasms 12Leukemia, Myeloid, Acute 12

Interventions

xaliproden 2Oxygen 2Polyamines 1Oxaliplatin 1Leucovorin 1Fluorouracil 12,2'-dithiodiethanesulfonic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Paresthesia × Leucovorin × Clear all
NCT00305188 2016-05-04

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

Sanofi

Phase 3 Completed
879 enrolled
Gastrointestinal

Neoplasm Metastasis, Paresthesia, Colorectal Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡